CNTB_OUT_1 [2025-04-15 17:04:44 -0400] 4612 Bytes | 1200 tokens | Cum: 1200 tkns (15.00% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Connect Biopharma (CNTB) hit my radar screen, up to 0.9079 from a prev close of 0.6509 Do you think its got more juice or is it lacking potential? It's 5:04:42 PM on Tue Apr 15, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: Connect Biopharma (CNTB)
IPO: 2021-03-19 (4 Years Ago)
Market Cap: $31,616,357
Shares Outstanding: 55,250,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Here’s a list of headlines for Connect Biopharma:

Apr-01-25 09:00AM - Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
Mar-31-25 04:05PM - Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
Mar-31-25 04:05PM 09:00AM - Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
Mar-28-25 04:05PM - Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Mar-03-25 08:00AM - Connect Biopharma to Present at Two Upcoming Investor Conferences
Oct-15-24 07:30AM - Attovia Therapeutics Appoints Chief Financial Officer
Sep-10-24 08:00AM - Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
Sep-05-24 04:05PM - Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Prior AI Reports for CNTB:
1. 2025-04-01 – Score: 1 – Target: 0.6600 – Highs: 0.7718 / 0.6800 / 0.67
bearish-momentum-prevails-amid-missing-financial-metrics

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-07-01T12:00:00Z - Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
B2 - 2024-06-12T22:03:00Z - Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
B3 - 2024-06-12T20:15:00Z - Connect Biopharma Announces New Leadership and Chair of the Board of Directors
B4 - 2024-05-22T20:05:00Z - Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
B5 - 2024-05-07T10:30:00Z - Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
B6 - 2024-04-16T20:05:00Z - Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Connect Biopharma (CNTB).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

CNTB_OUT_3 [2025-04-15 17:04:47 -0400] 1189 Bytes | 315 tokens | Cum: 1517 tkns (18.96% of 8k)
==========================================================================

Showing B4 (chunk 1 of 2): B4:
**Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/05/22/2886839/0/en/Connect-Biopharma-Presents-Late-Breaking-Abstract-at-the-American-Thoracic-Society-2024-International-Conference-on-the-Positive-Rademikibart-Data-from-its-Global-Phase-2b-in-Patie.htmlSAN DIEGO, CA and TAICANG, China, May 22, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today th

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CNTB_OUT_5 [2025-04-15 17:04:47 -0400] 579 Bytes | 154 tokens | Cum: 1673 tkns (20.91% of 8k)
==========================================================================

Showing B4 (chunk 2 of 2): at Edward Kerwin, M.D. presented a late-breaking poster presentation on the positive results from the rademikibart global Phase 2b trial in patients with moderate-to-severe asthma at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024 in San Diego, CA.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CNTB_OUT_7 [2025-04-15 17:04:48 -0400] 1017 Bytes | 294 tokens | Cum: 1969 tkns (24.61% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-11T13:26:16Z - Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show ...
A2 - 2025-04-11T13:02:00Z - RedChip Companies, Inc.: Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small St...
A3 - 2025-04-07T12:08:52Z - 12 Health Care Stocks Moving In Monday's Pre-Market Session - Bluejay Diagnostics (NASDAQ:BJDX), Bio...
A4 - 2025-04-04T15:48:07Z - Connect Biopharma stock hits 52-week low at $0.55 amid market challenges By Investing.com...
A5 - 2025-04-04T15:47:54Z - Connect Biopharma stock hits 52-week low at $0.55 amid market challenges By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CNTB_OUT_9 [2025-04-15 17:04:49 -0400] 1183 Bytes | 351 tokens | Cum: 2322 tkns (29.03% of 8k)
==========================================================================

Showing A1 (chunk 1 of 7): A1:
**Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV**Date: 2025-04-11Source: {'uri': 'streetinsider.com', 'dataType': 'news', 'title': 'StreetInsider.com'}URL: https://www.streetinsider.com/ACCESS+Newswire/Bullfrog+AI+and+Connect+Biopharma+Interviews+to+Air+on+the+RedChip+Small+Stocks%2C+Big+Money%28TM%29+Show+on+Bloomberg+TV/24629022.htmlORLANDO, FLORIDA / ACCESS Newswire / April 11, 2025 / RedChip Companies will air interviews with Bullfrog AI Holdings, Inc. (Nasdaq: BFRG) and Connect Biopharma Holdings Limited (Nasdaq: CNTB) and on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, April 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

In an exclusive interview, Vin Singh, Chief Executive Officer of Bullfrog AI, ap

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CNTB_OUT_11 [2025-04-15 17:04:50 -0400] 1187 Bytes | 241 tokens | Cum: 2565 tkns (32.06% of 8k)
==========================================================================

Showing A1 (chunk 2 of 7): pears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss how the company is revolutionizing drug discovery and development with Bullfrog Data Networks™, a cutting-edge platform powered by its proprietary bfLEAP™ technology. Designed for small and mid-sized biopharma companies, Bullfrog Data Networks enables users to harness high-dimensional, multi-modal datasets, uncovering hidden relationships and pathways to accelerate target identification, clinical trial optimization, and drug repurposing. By providing affordable, AI-powered insights, Bullfrog AI enhances decision-making and efficiency across the industry-helping resource-constrained organizations do more with less while enabling larger enterprises to optimize R&D investments and streamline drug development. In addition to driving growth through its Data Networks platform, Bullfrog AI continues to advance its port

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CNTB_OUT_13 [2025-04-15 17:04:50 -0400] 1184 Bytes | 253 tokens | Cum: 2820 tkns (35.25% of 8k)
==========================================================================

Showing A1 (chunk 3 of 7): folio of licensed drug assets and partnerships with world-class research institutions like the J. Craig Venter Institute and the Lieber Institute for Brain Development.

Barry Quart, CEO of Connect Biopharma, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's innovative therapeutics designed to transform the treatment landscape for inflammatory diseases driven by T-cell dysfunction. The company's lead candidate, rademikibart, is a next-generation, highly differentiated monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), with potential applications in asthma and chronic obstructive pulmonary disease (COPD)-markets collectively representing multi-billion-dollar commercial opportunities. Backed by robust clinical data from a global Phase 2 study demonstrating superior efficacy, rapid onset of action, and a favorable safety profile,

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CNTB_OUT_15 [2025-04-15 17:04:51 -0400] 1181 Bytes | 237 tokens | Cum: 3059 tkns (38.24% of 8k)
==========================================================================

Showing A1 (chunk 4 of 7): Connect is strategically positioned to enter clinical trials targeting acute exacerbations in respiratory diseases, an area of significant unmet medical need. With a newly strengthened U.S.-based management team experienced in successful drug development and regulatory execution, including having collectively received FDA marketing approval for 16 therapeutic products, and with deep expertise in business development, corporate strategy, finance and operations, Connect Biopharma is uniquely positioned as it moves toward pivotal clinical milestones and commercialization.

BFRG and CNTB are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.

About Bullfrog AI Holdings, Inc.

Bullfrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institu

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CNTB_OUT_17 [2025-04-15 17:04:52 -0400] 1184 Bytes | 273 tokens | Cum: 3334 tkns (41.68% of 8k)
==========================================================================

Showing A1 (chunk 5 of 7): tions, Bullfrog AI uses causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.

Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the company is advancing rademikibart, a next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. With an initial focus on acute exacerbations-an area with significant unmet need-rademikibart has the potential to also drive chronic utilization in asthma and COPD amongst the approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually. In a Phase 2 trial for asthma, rademikibart demonstrated strong efficacy and safety data

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CNTB_OUT_19 [2025-04-15 17:04:54 -0400] 1183 Bytes | 258 tokens | Cum: 3594 tkns (44.92% of 8k)
==========================================================================

Showing A1 (chunk 6 of 7): , with clinically meaningful reductions in exacerbations and rapid, statistically significant improvements in FEV, observed within one week-and in most cases, within 24 hours via home spirometry.

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CNTB_OUT_21 [2025-04-15 17:04:55 -0400] 833 Bytes | 180 tokens | Cum: 3776 tkns (47.20% of 8k)
==========================================================================

Showing A1 (chunk 7 of 7): platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

To learn more about RedChip's products and services, please visit:

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CNTB_OUT_23 [2025-04-15 17:04:57 -0400] 1116 Bytes | 282 tokens | Cum: 4062 tkns (50.78% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-01 8-K Item 7.01 Regulation FD Disclosure.

On April 1, 2025, Connect Biopharma Holdings Limited (the Company) issued a press release announcing positive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), Division of Pulmonology, Allergy, and Critical Ca...

S2 - 2025-04-01 8-K Item 7.01 Regulation FD Disclosure.

On April 1, 2025, Connect Biopharma Holdings Limited (the Company) issued a press release announcing positive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), Division of Pulmonology, Allergy, and Critical Ca...

S3 - 2025-03-31 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER.

The following discussion and analysis of our financial condition and results of operations should be read together with our audited financial statements and the related notes and othe...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CNTB_OUT_25 [2025-04-15 17:04:57 -0400] 1181 Bytes | 291 tokens | Cum: 4355 tkns (54.44% of 8k)
==========================================================================

Showing S1 (chunk 1 of 2): S1:
Item 7.01 Regulation FD Disclosure.

On April 1, 2025, Connect Biopharma Holdings Limited (the Company) issued a press release announcing positive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), Division of Pulmonology, Allergy, and Critical Care, in the Office of Immunology and Inflammation (the Type C Meeting). A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CNTB_OUT_27 [2025-04-15 17:04:58 -0400] 345 Bytes | 95 tokens | Cum: 4452 tkns (55.65% of 8k)
==========================================================================

Showing S1 (chunk 2 of 2): expressly set forth by specific reference in such a filing....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CNTB_OUT_29 [2025-04-15 17:05:06 -0400] 4969 Bytes | 1178 tokens | Cum: 5634 tkns (70.43% of 8k)
==========================================================================

This is our set of metrics for Connect Biopharma.
Please analyze the numbers.

+--------------------+-----------------------+-------------------------+-----------------------+
| Volume: 2,533,676 | Perf Month: 0.96% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 49.23K | Perf Quarter: -21.71% | Short Float: 0.01% | ROE: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 51.46 | Index: - | Short Ratio: 0.11 | ROI: -16.89% |
+--------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 59.67 | Market Cap: 45.93M | Short Interest: 0.01M | Sales Surprise: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 0.11 | Shs Outstand: 55.35M | Beta: -0.30 | EPS Surprise: -12.40% |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA20: 19.90% | Shs Float: 53.25M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA50: 2.48% | Inst Own: 5.74% | Sales past 5Y: 0.00% | Earnings: Mar 31 BMO |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA200: -23.11% | Insider Own: - | Employees: 62 | |
+--------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: 38.31% | Insider Trans: - | Debt/Eq: 0.00 | |
+--------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading by Connect Biopharma officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.829879
Average Volume: 219725.86
30-Day High: 0.829879
30-Day Low: 0.55
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Connect Biopharma (CNTB).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Connect Biopharma.

2) MARKET_SCORE[]
This conversation was initiated because CNTB is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for CNTB.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, CNTB could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect CNTB to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Connect Biopharma.

11) ETHICAL_RATING[]
Rate Connect Biopharma’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Connect Biopharma.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

CNTB_IN_31 [2025-04-15 17:05:06 -0400] 126 Bytes | 29 tokens | Cum: 5858 tkns (73.22% of 8k)
==========================================================================

====================================
[2025-04-15 17:05:06] # Analysis Completed
Elapsed Time: 23.44 seconds